CTOs on the Move

Polar Electro Inc

www.polarusa.com

 
Polar Electro Inc is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.polarusa.com
  • 1111 Marcus Ave Ste m15
    New Hyde Park, NY USA 11042
  • Phone: 516.364.0400

Executives

Name Title Contact Details

Similar Companies

Labviva

Revolutionizing life sciences procurement. AI-powered digital marketplace for complete transparency into your supply chain Labviva integrates with your existing purchasing software to provide you with actionable insights to make better decisions. Keep your current suppliers, contract pricing, and your purchasing software and processes. Our digital marketplace offers unparalleled visibility into your procurement process, to empower informed decisions to drive science forward without interruptions to your research.

Su International

Su International is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioStudio Visual Communications

BioStudio Visual Communications is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revance

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.